Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569723 · ClinicalTrials.gov registry record · NA
Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy
A NA study, sponsored by Edward Kim.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02569723 is a NA study that has completed, run by Edward Kim. The registered enrollment target is 6 participants.
The verdict
NCT02569723, a NA study, has completed, sponsored by Edward Kim.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carbon C 14 is a radioactive form of carbon, exists in nature and in the body at a low level. Microdose carbon C 14 oxaliplatin diagnostic assay may help doctors understand how well patients respond to treatment and develop individualize oxaliplatin dosing in patients with colorectal cancer.
Interventions
- DRUG Oxaliplatin
- DRUG Carbon C 14 Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10-16 |
| Est. Completion | 2020-04-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02569723
The ClinicalTrials.gov registry entry for NCT02569723 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edward Kim, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT02569723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02569723 about?
NCT02569723 is a clinical study titled "Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy". This pilot clinical trial studies how well carbon C 14 oxaliplatin microdosing assay works in predicting exposure and sensitivity to oxaliplatin-based chemotherapy in patients with colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment....
What is the current status of trial NCT02569723?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2015-10-16. Estimated completion is 2020-04-04.
What interventions are being tested in trial NCT02569723?
The interventions under investigation include: Oxaliplatin (DRUG), Carbon C 14 Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT02569723?
This trial is sponsored by Edward Kim, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.